Consultation record

Submissions accepted in part — page 13

Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.

Submissions

377 documents · page 13 of 13

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-RECONSTITUTI/005	Draft synthesis: Reconstitution practice and delivered dose	Dr Yehudit Yorkstone	The same concern is used to downgrade in two domains
DRAFT-RECONSTITUTI/006	Draft synthesis: Reconstitution practice and delivered dose	Dr Melisande Thorsby-Nakamura	Studies not published in English were excluded without assessment
DRAFT-RECONSTITUTI/004	Draft synthesis: Reconstitution practice and delivered dose	Radoslava Palmgren-Kofi industry	A sponsor trial meeting the eligibility criteria was excluded
DRAFT-RECONSTITUTI/001	Draft synthesis: Reconstitution practice and delivered dose	Dr Jacinta Steenkamp-Ferreira	Patient-reported outcomes are collected by the trials and not reported by the review
DRAFT-PANCREATITIS/002	Draft synthesis: Acute pancreatitis with incretin-based therapies	Dr Kamila Glendinning-Uche	The document is unreadable without specialist training
DRAFT-PANCREATITIS/005	Draft synthesis: Acute pancreatitis with incretin-based therapies	Ludmila Brackenridge	Statistical heterogeneity is treated as though it measured clinical heterogeneity
DRAFT-PRIMARY-VS-S/004	Draft synthesis: Cardiovascular benefit in primary compared with…	Dr Jolanta Uttridge	Subgroup findings are reported that were not registered in the protocol
DRAFT-PRIMARY-VS-S/010	Draft synthesis: Cardiovascular benefit in primary compared with…	Dr Ottoline Fitzgerald-Nwosu	The same concern is used to downgrade in two domains
DRAFT-TIRZEPATIDE-/003	Draft synthesis: Tirzepatide compared with semaglutide in type 2…	Dr Kamila Ubertini	Subgroup findings are reported that were not registered in the protocol
DRAFT-TIRZEPATIDE-/005	Draft synthesis: Tirzepatide compared with semaglutide in type 2…	Dr Theodora Ingelbrecht	Point estimates are given without an interval
DRAFT-PEPTIDE-PURI/001	Draft synthesis: Dependence of reported purity on the analytical…	Dr Anselm Ashworth-Danquah	The same concern is used to downgrade in two domains
DRAFT-PEPTIDE-PURI/002	Draft synthesis: Dependence of reported purity on the analytical…	Dr Bertrand Steenkamp-Ferreira	The document is unreadable without specialist training
DRAFT-MITOCHONDRIA/001	Draft synthesis: Mitochondria-targeted peptides in bioenergetic…	Zdenka Ximenes	Statistical heterogeneity is treated as though it measured clinical heterogeneity
DRAFT-MITOCHONDRIA/005	Draft synthesis: Mitochondria-targeted peptides in bioenergetic…	Ludmila Brackenridge	Subgroup findings are reported that were not registered in the protocol
DRAFT-MITOCHONDRIA/003	Draft synthesis: Mitochondria-targeted peptides in bioenergetic…	Dr Liesbeth Zaleski-Mbeki	The review protocol is described but its registration record is not linked
DRAFT-MITOCHONDRIA/009	Draft synthesis: Mitochondria-targeted peptides in bioenergetic…	Dr Adaeze Dunmore-Ekpo industry	A sponsor trial meeting the eligibility criteria was excluded
DRAFT-MITOCHONDRIA/010	Draft synthesis: Mitochondria-targeted peptides in bioenergetic…	Dr Wilhelmina Erlingsson	The document is unreadable without specialist training

page 13 of 13